Filing Analysis
Radnostix Inc. held its 2026 Annual Meeting of Shareholders on July 16, 2026, where shareholders approved the election of five directors and a new equity incentive plan. The meeting also included the ratification of Haynie & Company as the company's independent auditor for the 2026 fiscal year.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on July 16, 2026, with a quorum representing approximately 58.46% of outstanding shares (309,307,669 shares).
- Shareholders approved the 'Radnostix Inc. 2026 Incentive Plan', which allows for the issuance of up to 12,000,000 shares of common stock.
- Five directors (Robert Atcher, Shahe Bagerdjian, Duke Fu, Christopher Grosso, and Steve Laflin) were elected to one-year terms.
- Haynie & Company was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Radnostix, Inc. entered into multiple significant agreements involving the Chairman and CEO, including a $500,000 convertible note with a company-controlled entity and amendments to several 'historic' notes held by insiders. The company also acquired technology assets via an asset purchase agreement involving significant equity components.
🚩 Red Flags
- Multiple related-party transactions involving the Chairman and CEO (Note Agreement and Note Amendments).
- Significant dilution risk due to multiple convertible instruments with low conversion prices ($0.07) relative to potential market value.
- Extension of 'Historic Notes' suggests long-term debt obligations to insiders that have been outstanding since 2013, 2018, and 2019.
📋 Key Facts
- Purchased Lara System/Ellexa Explorer assets from Lucerno Dynamics, LLC for $150,000 cash and $750,000 in common stock (June 25, 2026).
- Issued a $500,000 convertible promissory note to Kershner Grosso & Co., owned by Chairman Christopher Grosso (June 23, 2026).
- The Note has a conversion price of $0.07 per share and a maturity date of June 30, 2031.
- Amended 'Historic Notes' totaling approximately $1.62M held by the Chairman, CEO, and other major shareholders; these notes were extended to March 31, 2031.
- The amendments include a voluntary lender conversion right at $0.07 per share for all historic notes.
International Isotopes Inc. has officially changed its corporate name to Radnostix, Inc. following shareholder approval. This rebranding reflects a strategic shift from energy-sector isotopes toward healthcare applications, specifically radioisotopes and theranostics.
📋 Key Facts
- Corporate name changed from International Isotopes Inc. to Radnostix, Inc.
- The change was approved by the Board of Directors on October 21, 2025.
- A majority of shareholders approved the change via written consent on November 25, 2025.
- The company will continue to trade under the ticker symbol 'INIS' on the OTCQB marketplace.
- Strategic pivot: Moving from radiochemicals/energy isotopes to healthcare-focused radioisotopes and theranostics.
International Isotopes Inc. announced a new employment agreement for CEO Shahe Bagerdjian, the appointment of Dr. Duke W. Fu to the Board and Audit Committee, and several amendments to the company's bylaws.
🚩 Red Flags
- Significant equity compensation (37.5M RSUs) tied to very low share price targets ($0.10 - $0.30), which may indicate a highly distressed stock price or significant dilution risk.
- Bylaw amendments grant the Board increased power to postpone, reschedule, or cancel special meetings of shareholders.
📋 Key Facts
- CEO Shahe Bagerdjian entered into a new employment agreement effective October 10, 2025, with a term running through July 18, 2030.
- Bagerdjian's base salary is $314,000 per year with automatic 5% annual increases and potential $50,000 increases based on quarterly revenue milestones (up to $25M).
- The CEO was awarded 37.5 million RSUs with vesting tied to specific share price triggers ranging from $0.10 to $0.30.
- Dr. Duke W. Fu, a nuclear pharmacist and pharmaceutical executive, appointed to the Board and Audit Committee; he will receive 250,000 RSUs per annual term.
- Bylaw amendments include new procedures for advance notice of director nominations and shareholder business, as well as provisions for advisory directors.
International Isotopes Inc. announced a new employment agreement for CEO Shahe Bagerdjian, including significant performance-based RSU tranches and salary milestones. Additionally, the company appointed Dr. Duke W. Fu to its Board and Audit Committee and approved several amendments to its corporate bylaws.
🚩 Red Flags
- Significant equity dilution potential: The CEO was awarded 37.5 million RSUs with very low share price triggers ($0.10 - $0.30), suggesting a highly distressed or low-priced stock environment.
- Bylaw changes regarding 'Special Meetings' and 'Advance Notice Procedures' often grant more control to the Board, potentially limiting shareholder activism.
📋 Key Facts
- CEO Shahe Bagerdjian entered a new employment agreement effective October 10, 2025, with a term through July 18, 2030.
- Bagerdjian's base salary is $314,000 with automatic 5% annual increases and potential $50,000 increases based on quarterly revenue milestones (up to $25M).
- The CEO was awarded 37.5 million RSUs with vesting tied to specific share price triggers ranging from $0.10 to $0.30.
- Dr. Duke W. Fu, a pharmaceutical executive and nuclear pharmacist, appointed to the Board and Audit Committee.
- Dr. Fu to receive 250,000 RSUs annually for each term served.
- Bylaw amendments include new procedures for advance notice of director nominations and shareholder business, as well as provisions for advisory directors.
International Isotopes Inc. held its 2025 Annual Meeting of Shareholders where shareholders approved a significant amendment to the Certificate of Formation to authorize a reverse stock split with a ratio between 1-for-50 and 1-for-275.
🚩 Red Flags
- Approval of a massive reverse stock split (up to 1-for-275) is often used to combat low share prices or prevent delisting.
- The wide range of the potential split ratio suggests significant volatility or uncertainty regarding the target price.
📋 Key Facts
- Annual Meeting held on July 10, 2025.
- Quorum represented approximately 61.6% of outstanding shares (324,450,180 shares).
- Shareholders approved a reverse stock split ratio between 1-for-50 and 1-for-275.
- Four directors were elected: Robert Atcher, Shahe Bagerdjian, Christopher Grosso, and Steve T. Laflin.
- Ratification of Haynie & Company as independent auditors for fiscal year ending Dec 31, 2025 was approved.
- Shareholders voted to hold advisory votes on executive compensation every three years (90.1% in favor).
- Proposal 5 (Reverse Split) passed with significant majority: 312,456,245 'For' vs 10,309,627 'Against'.
International Isotopes Inc. has successfully modified the maturity date of its Series C Convertible Redeemable Preferred Stock. The modification extends the maturity deadline by two years, moving it from an earlier date to February 28, 2027.
🚩 Red Flags
- The need for a maturity extension often indicates liquidity management or cash flow constraints regarding preferred stock obligations.
📋 Key Facts
- Approval was received on September 25, 2024, from a majority of outstanding Series C Preferred Stock holders.
- The maturity date for the Series C Preferred Stock is extended by two years to February 28, 2027.
- A Certificate of Amendment to Statement of Designation was filed with the Secretary of State of Texas on September 26, 2024.
- All other terms of the Series C Preferred Stock remain unchanged.
International Isotopes Inc. held its 2024 Annual Meeting of Shareholders on July 10, 2024. The filing reports the election of four directors and the ratification of Haynie & Company as the independent auditor.
📋 Key Facts
- Annual Meeting held on July 10, 2024, in Idaho Falls, Idaho.
- Quorum was established with 269,004,293 shares (approx. 51.4% of outstanding common stock) represented.
- Robert Atcher, Shahe Bagerdjian, Christopher Grosso, and Steve T. Laflin were elected to the Board of Directors for one-year terms.
- Haynie & Company was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
International Isotopes Inc. has entered into an Asset Purchase Agreement to sell its depleted uranium deconversion and fluorine extraction plant (DUF6 Plant) to American Fuel Resources, LLC. The transaction is expected to close in 12 to 24 months, subject to NRC license transfers.
🚩 Red Flags
- Long execution timeline (12-24 months) creates significant uncertainty regarding the realization of cash proceeds.
- Transaction is contingent upon complex regulatory approval (NRC License Transfer).
📋 Key Facts
- Agreement date: February 8, 2024
- Buyer: American Fuel Resources, LLC (AFR)
- Asset being sold: Depleted uranium deconversion and fluorine extraction plant (DUF6 Plant) assets and certain liabilities.
- Total consideration: $12,550,000 ($50,000 prepayment + $12,500,000 at closing).
- Estimated timeline to close: 12 to 24 months.
- Closing conditions include the transfer of U.S. Nuclear Regulatory Commission (NRC) licenses and other purchased assets.